- Home
- LXP vs MIRM Comparison
LXP vs MIRM Comparison
Compare LXP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- MIRM
- Stock Information
- Founded
- LXP 1993
- MIRM 2018
- Country
- LXP United States
- MIRM United States
- Employees
- LXP N/A
- MIRM N/A
- Industry
- LXP Real Estate Investment Trusts
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- MIRM Health Care
- Exchange
- LXP Nasdaq
- MIRM Nasdaq
- Market Cap
- LXP 2.5B
- MIRM 2.1B
- IPO Year
- LXP 1993
- MIRM 2019
- Fundamental
- Price
- LXP $8.45
- MIRM $47.98
- Analyst Decision
- LXP Buy
- MIRM Strong Buy
- Analyst Count
- LXP 3
- MIRM 11
- Target Price
- LXP $11.50
- MIRM $57.00
- AVG Volume (30 Days)
- LXP 2.4M
- MIRM 432.9K
- Earning Date
- LXP 02-13-2025
- MIRM 02-26-2025
- Dividend Yield
- LXP 6.46%
- MIRM N/A
- EPS Growth
- LXP N/A
- MIRM N/A
- EPS
- LXP 0.06
- MIRM N/A
- Revenue
- LXP $340,563,000.00
- MIRM $307,028,000.00
- Revenue This Year
- LXP N/A
- MIRM $82.63
- Revenue Next Year
- LXP $3.47
- MIRM $26.43
- P/E Ratio
- LXP $130.79
- MIRM N/A
- Revenue Growth
- LXP 0.56
- MIRM 112.14
- 52 Week Low
- LXP $7.65
- MIRM $23.14
- 52 Week High
- LXP $10.57
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- LXP 52.96
- MIRM 68.78
- Support Level
- LXP $7.65
- MIRM $45.26
- Resistance Level
- LXP $8.31
- MIRM $47.25
- Average True Range (ATR)
- LXP 0.21
- MIRM 1.56
- MACD
- LXP 0.08
- MIRM 0.66
- Stochastic Oscillator
- LXP 97.55
- MIRM 91.60
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. Majority of the revenue is earned through rental revenue.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.